To view this email as a web page, click here.
 
Oncology Pipeline Predictions
From our sister publication, Managed Healthcare Executive: This year has been another year full of oncology approvals, proving that the oncology pipeline is robust with first-of-the kind molecules, competitor products for existing agents, and biosimilars.
Read more
ADVERTISEMENT
 
Pharma exec defends 400% price hike
Reminiscent of former Turing Pharmaceuticals CEO Martin Shrekli, a different pharma executive defended his company’s 400% price hike on an antibiotic.
Read more
 
Cancer drug prices rise despite Trump plan
The manufacturer of 2 cancer drugs hiked the price on the medicines, despite President Trump’s new plan to lower drug prices.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.